

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claim 1 (currently amended): A method for treating a patient suffering from colorectal cancer proliferative disease, said method comprising administering an effective amount of epothilone B the step of daily administration over 1 to 14 days, of a therapeutically effective amount of an epothilone, together with a pharmaceutically acceptable carrier, to a warm-blooded animal in need of such treatment, wherein the daily administration is by continuous intravenous (i.v.) administration lasting 6 to 24 hours.

Claim 2 (canceled)

Claim 3 (currently amended): The method according to claim 1 where an wherein epothilone B is used in more than one treatment cycle, wherein a treatment cycle consists of a dosing period from 1 day to 2 weeks and a resting period from 6 days to 10 weeks, wherein the dosing period may not be shorter than the administration over 1 to 14 days.

Claim 4 (currently amended): The method according to claim 1 where epothilone B is used in a dose in humans that is between 4.0 mg/m<sup>2</sup> and 10 mg/m<sup>2</sup>.

Claim 5 (currently amended): The method according to claim 1 where epothilone B is used in a dose in humans that is between 5 mg/m<sup>2</sup> and 10 mg/m<sup>2</sup>.

Claim 6 (previously presented): The method according to claim 1 where epothilone B is used in a dose that is between 5.4 mg/m<sup>2</sup> and 8 mg/m<sup>2</sup>.

Claim 7 (previously presented): The method according to claim 1 where epothilone B is used in a dose that is between between 7 mg/m<sup>2</sup> and 8 mg/m<sup>2</sup>.

Claim 8 (previously presented): The method ~~for~~ according to claim 1 where epothilone B is administered by intravenous infusion over 1 to 10 days.

Claim 9 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 1 to 7 days.

Claim 10 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 1 to 5 days.

Claim 11 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 1 day.

Claim 12 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 5 days.

Claims 13-24 (canceled)

Claim 25 (currently amended): The method according to claim 13-1 wherein the ~~tumor to be treated is a colorectal tumor that~~ cancer is refractory to standard chemotherapy.

Claims 26-27 (canceled)

Claim 28 (currently amended): The method according to claim 27-1 where the ~~proliferative disease to be treated is a colorectal~~ cancer ~~tumor that~~ is refractory to ~~at least~~ 5-fluorouracil[.] and/or to standard chemotherapy.

Cal m s 2(-9 4 1 ) c. a n c e l e d